Flibanserin is utilized for hypoactive sexual interest disorder among women. Those receiving flibanserin report that the normal amount of times they had “satisfying sexual events” rose from 2.8 to 4.5 times 30 days. However, women receiving placebo reported also an increase of “satisfying sexual events” from 2.7 to 3.7 times monthly. Evaluation of the overall improvement of these condition and perhaps the benefit was meaningful for the women, showed an extremely higher rate of the meaningful benefit from the flibanserin-treated people versus the placebo group.The start the flibanserin effect was seen from the first timepoint measured after Four weeks of treatment and maintained during the entire treatment period.
The effectiveness of flibanserin was evaluated in three phase 3 clinical studies. All the three trials had two co-primary endpoints, one for satisfying sexual events (SSEs) and also the other for virility. Each one of the 3 trials also had a secondary endpoint that measured distress linked to sexual desire.
The three trials indicated that flibanserin produced a statistically significant rise in the amount of SSEs and reduced distress associated with virility.
The 1st two trials used an electronic diary to determine sexual interest, and failed to locate a statistically significant increase when compared with women addressed with a placebo. These two trials also measured libido while using the Female Sexual Function index (FSFI) like a secondary endpoint, plus a statistically significant increase was observed applying this latter measure. The FSFI was utilized because co-primary endpoint for sexual interest in the third trial, and again showed a statistically significant increase.